跳至主要内容
临床试验/NCT01362491
NCT01362491已完成3 期

Ibuprofen Sodium Tension Headache Study

Pfizer1 个研究点 分布在 1 个国家目标入组 226 人开始时间: 2011年6月最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
发起方
Pfizer
入组人数
226
试验地点
1
主要终点
Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-3 Hours (SPRID 0-3) for Ibuprofen Sodium Versus Placebo Tablet

研究概览

简要总结

This study will compare the ability of a single-dose of a novel ibuprofen formulation to relieve pain compared to placebo and standard ibuprofen in the treatment of tension-type headache

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males and females at least 18 years to 65 years of age
  • A diagnosis of an episodic tension-type headache, as defined by the International Headache Society

排除标准

  • Pregnancy or breast-feeding
  • Alcohol or substance abuse
  • Any serious medical or psychiatric disorder

研究组 & 干预措施

Treatment A

Experimental

干预措施: Ibuprofen Sodium (Drug)

Treatment B

Active Comparator

干预措施: Standard Ibuprofen (Drug)

Treatment C

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-3 Hours (SPRID 0-3) for Ibuprofen Sodium Versus Placebo Tablet

时间窗: 0-3 Hours

SPRID:time-weighted sum of pain relief rating combined with pain intensity difference (PRID) over 3 hours. SPRID score range:-3 (worst) to 21 (best) for SPRID 0-3. PRID: sum of pain intensity differences (PID) and pain relief rating(PRR) at each time point. PRID score range: -1=worst to 7=best. PID: baseline pain severity score minus pain severity score at a given time point (score range 0=none to 3=severe; baseline score range 2=moderately severe to 3=severe). Total score range for PID: -1(worst) to 3 (best). PRR:assessed on 5-point pain relief rating scale (0=No relief to 4=Complete relief).

Time to Onset of Meaningful Relief for Ibuprofen Sodium Versus Ibuprofen (Motrin IB) Tablet

时间窗: 0 to 3 hours

Participants evaluated the time to meaningful relief by stopping a second stopwatch labeled 'meaningful relief' at the moment the participant first began to experience meaningful relief. It was also considered achieved if the participant stated "meaningful relief" at the time the first stopwatch was depressed. Stopwatch was active up to 3 hours after dosing or until stopped by the participant, or rescue medication was administered.

次要结局

  • Time to Confirmed First Perceptible Relief(0 to 3 hours)
  • Pain Relief Rating (PRR)(1, 2 & 3 hours post-dose)
  • Pain Intensity Difference (PID)(1, 2 & 3 hours post-dose)
  • Time-weighted Sum of Pain Relief Rating (TOTPAR)(0 to 2, 0 to 3 hours)
  • Cumulative Percentage of Participants With Meaningful Relief(0.5, 1, 2, 3 hours)
  • Cumulative Percentage of Participants With First Perceptible Relief(0.5, 1, 2, 3 hours)
  • Duration of Relief(0 to 3 hours)
  • Time to Onset of Meaningful Relief: Remaining Comparisons(0 to 3 hours)
  • Sum of Pain Relief Rating and Pain Intensity Difference (PRID)(1, 2 & 3 hours post-dose)
  • Time-weighted Sum of Pain Intensity Difference (SPID)(0 to 2, 0 to 3 hours)
  • Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference (SPRID)(0 to 2, 0 to 3 hours)
  • Cumulative Percentage of Participants With Treatment Failure(1, 2, 3 hours post-dose)
  • Cumulative Percentage of Participants With Complete Relief(1, 2, & 3 hours post-dose)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验